Astria Therapeutics Inc., a biopharmaceutical company focused on developing therapies for allergic and immunologic diseases, will present at the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary, on May 31, 2025. Dr. Marc A. Riedl will present safety and efficacy data from the Phase 1a and Phase 1b/2 trials of navenibart in a presentation titled, "Navenibart for Hereditary Angioedema $(HAE)$: Analysis of Safety, Pharmacokinetic, and Pharmacodynamic Data From Phase 1a and Phase 1b/2 ALPHA-STAR Trial."
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。